Vitrafy Life Sciences Limited has released a press release.
Q2 FY25 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Vitrafy Life Sciences Ltd. on 6ix
Later from Vitrafy Life Sciences
- FY25 Half Year Results Presentation
- FY25 Appendix 4D and Half Year Report
- Vitrafy Awarded Industry Growth Program Grant
- USAISR successful Phase 1 Blood Platelet study
- Q3 FY25 Quarterly Activities Report and Appendix 4C
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences